Coping with uncertainty: T1a,bNOMO HER2-positive breast cancer, do we have a treatment threshold?KELLY, C. M; PRITCHARD, K. I; TRUDEAU, M et al.Annals of oncology. 2011, Vol 22, Num 11, pp 2387-2393, issn 0923-7534, 7 p.Article

Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancerGAJRIA, Devika; GONZALEZ, Joseph; HUDIS, Clifford A et al.Breast cancer research and treatment. 2012, Vol 131, Num 1, pp 111-116, issn 0167-6806, 6 p.Article

Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysisZAGOURI, Flora; SERGENTANIS, Theodoros N; BARTSCH, Rupert et al.Breast cancer research and treatment. 2013, Vol 139, Num 1, pp 13-22, issn 0167-6806, 10 p.Article

A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancerJOHNSTON, Stephen R. D; GÓMEZ, Henry; STEMMER, Salomon M et al.Breast cancer research and treatment. 2013, Vol 137, Num 3, pp 755-766, issn 0167-6806, 12 p.Article

Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumabGRADISHAR, W. J.Annals of oncology. 2013, Vol 24, Num 10, pp 2492-2500, issn 0923-7534, 9 p.Article

Therapeutic approaches for HER2-positive brain metastases: Circumventing the blood―brain barrierMENTA, AnkitI; BRUFSKY, Adam M; SAMPSON, John H et al.Cancer treatment reviews. 2013, Vol 39, Num 3, pp 261-269, issn 0305-7372, 9 p.Article

Patient-Reported Outcomes From EMILIA, a Randomized Phase 3 Study of Trastuzumab Emtansine (T-DM1) Versus Capecitabine and Lapatinib in Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Breast CancerWELSLAU, Manfred; DIERAS, Veronique; SOHN, Joo-Hyuk et al.Cancer. 2014, Vol 120, Num 5, pp 642-651, issn 0008-543X, 10 p.Article

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancerRUGO, Hope S; BRUFSKY, Adam M; YOOD, Marianne Ulcickas et al.Breast cancer research and treatment. 2013, Vol 141, Num 3, pp 461-470, issn 0167-6806, 10 p.Article

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational studyKAUFMAN, Peter A; BRUFSKY, Adam M; MAYER, Musa et al.Breast cancer research and treatment. 2012, Vol 135, Num 3, pp 875-883, issn 0167-6806, 9 p.Article

Brain metastases in HER2-positive breast cancer: The evolving role of lapatinibTOMASELLO, Gianluca; BEDARD, Philippe L; DE AZAMBUJA, Evandro et al.Critical reviews in oncology/hematology. 2010, Vol 75, Num 2, pp 110-121, issn 1040-8428, 12 p.Article

Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in CaliforniaPARISE, Carol; CAGGIANO, Vincent.Cancer epidemiology (Print). 2014, Vol 38, Num 5, pp 556-562, issn 1877-7821, 7 p.Article

Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trialsBRIA, Emilio; CARBOGNIN, Luisa; SPERDUTI, Isabella et al.Cancer treatment reviews. 2014, Vol 40, Num 7, pp 847-856, issn 0305-7372, 10 p.Article

Trastuzumab in small tumours and in elderly womenALBANELL, Joan; CIRUELOS, Eva M; LLUCH, Ana et al.Cancer treatment reviews. 2014, Vol 40, Num 1, pp 41-47, issn 0305-7372, 7 p.Article

Phase I Study of S-1 in Combination with Trastuzumab for HER2-positive Metastatic Breast CancerNAKAYAMA, Takahiro; MORITA, Satoshi; TAKASHIMA, Tsutomu et al.Anticancer research. 2011, Vol 31, Num 9, pp 3035-3039, issn 0250-7005, 5 p.Article

Case histories: breast cancerGENNARI, Alessandra; PIETRI, Elisabetta; AMADORI, Dino et al.European journal of cancer. Supplement (1990). 2011, Vol 9, Num 2, pp 36-42, issn 1359-6349, 7 p.Article

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHERYARDLEY, D. A; TRIPATHY, D; BRUFSKY, A. M et al.British journal of cancer. 2014, Vol 110, Num 11, pp 2756-2764, issn 0007-0920, 9 p.Article

Soluble Human Epidermal Growth Factor Receptor 2 (HER2) Levels in Patients With HER2-Positive Breast Cancer Receiving Chemotherapy With or Without Trastuzumab: Results From North Central Cancer Treatment Group Adjuvant Trial N9831MORENO-ASPITIA, Alvaro; HILLMAN, David W; KUTTEH, Leila A et al.Cancer. 2013, Vol 119, Num 15, pp 2675-2682, issn 0008-543X, 8 p.Article

Growth Effect of Neutrophil Elastase on Breast Cancer: Favorable Action of Sivelestat and Application to Anti-HER2 TherapyNAWA, Masahito; OSADA, Shinji; MORIMITSU, Kasumi et al.Anticancer research. 2012, Vol 32, Num 1, pp 13-19, issn 0250-7005, 7 p., aArticle

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancerMINUTI, G; CAPPUZZO, F; JANKOWSKI, T et al.British journal of cancer. 2012, Vol 107, Num 5, pp 793-799, issn 0007-0920, 7 p.Article

A Phase 1 Study of Weekly Dosing of Trastuzumab Emtansine (T-DM1) in Patients With Advanced Human Epidermal Growth Factor 2―Positive Breast CancerBEERAM, Muralidhar; KROP, Ian E; BURRIS, Howard A et al.Cancer. 2012, Vol 118, Num 23, pp 5733-5740, issn 0008-543X, 8 p.Article

A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancerYARDLEY, Denise; BURRIS, Howard; PEACOCK, Nancy et al.Breast cancer research and treatment. 2010, Vol 123, Num 2, pp 471-475, issn 0167-6806, 5 p.Article

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : updated efficacy and biomarker analysesCAMERON, David; CASEY, Michelle; CHAN, Arlene et al.Breast cancer research and treatment. 2008, Vol 112, Num 3, pp 533-543, issn 0167-6806, 11 p.Article

Trastuzumab Combined with Docetaxel-Based Regimens in Previously Treated Metastatic Gastric Cancer Patients with HER2 Over-ExpressionDAI, Guang-Hai; YAN SHI; LI CHEN et al.Hepato-gastroenterology. 2012, Vol 59, Num 120, pp 2439-2444, issn 0172-6390, 6 p.Article

Present and future breast cancer management-bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industryBARTSCH, R; FRINGS, S; HENDRIKS, H. R et al.Annals of oncology. 2014, Vol 25, Num 4, pp 773-780, issn 0923-7534, 8 p.Article

Anti-cancer activity profile of 3'-azidothymidine 5'-[p-methoxyphenyl methoxyalaninyl phosphate] (compound 003), a novel nucleoside analogUCKUN, Fatih M; VASSILEV, Alexei O; DIBIRDIK, Ilker et al.Arzneimittel-Forschung. 2004, Vol 54, Num 11, pp 715-731, issn 0004-4172, 17 p.Article